US: Mead Johnson lifts sales forecast after "strong" Q1
Mead Johnson shares jumped on improved forecasts
Infant formula supplier Mead Johnson has raised its forecasts for annual sales and underlying earnings, sending shares in the US group climbing today (24 April).
"We now anticipate constant dollar sales growth of approximately eight per cent for the full year 2014, up from seven per cent in our prior guidance, on expected stronger revenue momentum," Mead Johnson CEO Kasper Jakobsen as he reported the Enfamil group's first-quarter results.
Jakobsen said Mead Johnson had generated "record" sales and earnings in the quarter. "Sales growth was strong across all segments, including within our two largest markets. With innovations launched last year and increased investment in demand creation, we continued to see market share gains in all three segments. We invested appropriately to support future growth, while delivering 16 percent growth in earnings per share on a non-GAAP basis."
Mead Johnson also predicted its non-GAAP earnings per share would hit US$3.60-3.72, up from its earlier forecast of $3.50 to $3.62.
Non-GAAP net earnings per diluted share were $1.02 for the quarter to 31 March, up from $0.88 a year earlier. Net earnings increased 9.4% to $207.8m. EBIT rose 6.7% to $291.2m.
First-quarter sales were $1.11bn 7% higher than a year ago. Sales were up 11% on a constant dollar basis.
Shares in Mead Johnson were up 4.08% at $87.71 at 12:55 ET.
|Mead Johnson Reports Strong First Quarter Earnings; Delivers 11 Percent Constant Dollar Sales Growth; And Increases Annual Guidance|
GLENVIEW, Ill.--(BUSINESS WIRE)--Apr. 24, 2014-- Mead Johnson Nutrition Company (NYSE: MJN) today announced its financial results for the quarter endedMarch 31, 2014.
(1) For the definition of Specified Items and a reconciliation of GAAP and non-GAAP results, see “Non-GAAP Financial Measures” on the schedule titled “Supplemental Financial Information” included in this release.
“We achieved record sales and earnings in the quarter,” said Chief Executive Officer Kasper Jakobsen. “Sales growth was strong across all segments, including within our two largest markets. With innovations launched last year and increased investment in demand creation, we continued to see market share gains in all three segments. We invested appropriately to support future growth, while delivering 16 percent growth in earnings per share on a non-GAAP basis.”
First Quarter Results
Sales for the first quarter of 2014 were $1,113.3 million, up seven percent from $1,037.9 million a year ago. Sales increased seven percent from volume and four percent from price, partially offset by a four percent decline from foreign exchange. Gross margin for the first quarter of 2014 was 63.6 percent, up from 62.9 percent in the first quarter of the prior year. The gross margin improvement was due to pricing and productivity gains, somewhat offset by higher dairy costs. Advertising and promotion investments grew in line with sales growth. Operating expenses were higher mainly due to the impact of a 2013 pension MTM actuarial gain not repeated in 2014. Earnings before interest and income taxes (“EBIT”) totaled $291.2 million, up from $273.5 million in the prior-year quarter.
The company’s effective tax rate (“ETR”) was 25.5 percent in the first quarter, compared to 26.7 percent in the prior-year quarter. The ETR improvement was primarily attributed to a change in the geographic earnings mix.
Net earnings attributable to shareholders totaled $202.4 million, or $1.00 per diluted share, in the first quarter of 2014, compared to $188.0 million, or $0.92 per diluted share, in the prior-year quarter.
On a non-GAAP basis, which excludes Specified Items, net earnings attributable to shareholders totaled $206.1 million, or $1.02 per diluted share, for the first quarter of 2014, compared to $179.9 million, or $0.88 per diluted share, for the same quarter a year ago.
First Quarter Segment Results
The Asia segment reported sales of $592.7 million for the first quarter of 2014, up seven percent from $554.2 million in the prior-year quarter. Sales increased six percent from volume and three percent from price, reduced by two percent from foreign exchange. Volume growth was driven by category growth and market share gains. Several Asian markets, including China, saw a continued benefit from competitors' supply disruptions that occurred in 2013. EBIT for the Asiasegment totaled $241.3 million in the first quarter of 2014, up from $221.6 million for the same quarter a year ago. The increase in EBIT was mainly driven by higher sales.
The Latin America segment reported sales of $212.4 million for the first quarter of 2014, up six percent from $201.1 million in the same period of the prior year. Sales increased 11 percent from price and 10 percent from volume offset by a 15 percent foreign exchange decline. Price increases in Venezuela and Argentinasubstantially mitigated the unfavorable sales impact from weaker local currencies in both markets. Volume growth was driven by share gains across most markets and continued category growth. Operating expenses were up due to a receivable allowance for a pharmacy distributor in Mexico and a Venezuelan balance sheet remeasurement loss. Effective February 28, 2014, the company adopted the Venezuelan government-supported rate, commonly referred to as SICAD I. EBIT for the Latin America segment totaled $46.6 million in the first quarter of 2014, from $47.0 million for the same quarter a year ago.
The North America/Europe segment reported sales of $308.2 million for the first quarter of 2014, up nine percent from $282.6 million in the first quarter of 2013. Sales increased seven percent from volume and two percent from price. Volume growth was primarily in the U.S. driven by an expanding children's nutrition business, non-WIC (2) market share gains and retailer inventory adjustments. Gross margin improved from pricing, manufacturing efficiencies and timing of WIC accruals. Higher demand-generation spending helped to drive growth in children's nutrition products. EBIT for the North America/Europe segment totaled $66.1 million in the first quarter of 2014, up 25 percent from $52.9 million in the first quarter a year ago.
Corporate and Other expenses increased mainly due to legal costs and the impact of a 2013 pension MTM actuarial gain not repeated in 2014.
(2) The Special Supplemental Nutrition Program for Women, Infants and Children (WIC) is a federal assistance program of the Food and Nutrition Services (FNS) of the United States Department of Agriculture (USDA).
Outlook for 2014
“We now anticipate constant dollar sales growth of approximately eight percent for the full year 2014, up from seven percent in our prior guidance, on expected stronger revenue momentum,” Mr. Jakobsen said. “We are planning for higher demand-generating investments throughout the remainder of the year, despite foreign exchange pressure on our earnings.” With the New Pension Accounting changes and stronger underlying business performance, the company has raised guidance and expects full-year non-GAAP EPS to be in the range of $3.60 to $3.72 per diluted share.
Original source: Mead Johnson
Mead Johnson remains the leader in milk formula in China. However, this market is undergoing changes which may intensify competition going forward. Meanwhile, public perception of infant milk formula ...
TechNavio's Analysts forecast the Global Baby Food and Formula market to grow at a CAGR of 5.4 percent over the period 2012-2016. One of the key factors contributing to this market growth is the growi...
Synopsis Baby Food Canada examines the trends in the baby food market for 2006-2012, with forecasts to 2018. It examines how live birth rates, breastfeeding trends, the economic crisis, new product a...
TechNavio's analysts forecast the Baby Food and Formula market in the US to grow at a CAGR of 2.76 percent over the period 2013-2018. One of the key factors contributing to this market growth is the i...
This report analyzes the worldwide markets for Clinical Nutrition Products in US$ Million by the following Product Segments: Enteral Nutrition, Infant Nutrition, and Parenteral Nutrition. The report p...
This report analyzes the worldwide markets for Baby Foods and Infant Formula in US$ by the following Product Segments: Infant Formula (Baby Milks/Baby Formulas), Baby Meals, Baby Cereals, Baby Juices/...
- On the money: Hormel still looking for M&A
- Consuming issues: The hunger-obesity paradox
- BRICs and beyond: Fonterra, Beingmate partnership
- On the money: Hain expects continued organic gains
- Analysis: Market bets on higher Chiquita offer
- Fonterra, Beingmate launch infant formula JV
- Mondelez eyes snacks categories in India
- Parmalat nears Lacteos Brasil acquisition
- Switz rejects EU plea to bypass Russia export ban
- Italy yoghurt woes lead to Emmi profit warning